News of Note—Vical, FluGen and more

In this week's news of note, Vical announced a restructuring. (Pixabay)

Here's some other vaccine news of note for the week:

> After its Astellas-partnered CMV vaccine failed a late-stage trial last week, Vical announced it's laying off 40 employees and focusing its efforts on an HSV-2 vaccine candidate and an antifungal drug. FierceBiotech story | More

> FluGen is planning a new study in Europe for its universal flu vaccine candidate. Wisconsin State Journal article

> The University of Tokyo entered a cancer vaccine partnership with the Kanagawa Cancer Center and BrightPath Biotherapeutics. Release